Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Noven Pharmaceuticals, Inc.
WARNING LETTER
•Noven Pharmaceuticals, Inc.•February 14, 2011

Noven Pharmaceuticals, Inc. – FDA Warning Letter, Feb 14, 2011

Record Details

An FDA inspection of Noven Pharmaceuticals, Inc. in Carlsbad, California, from January 31 to February 14, 2011, identified significant Current Good Manufacturing Practice (CGMP) violations for Finished Pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. § 351(a)(2)(B). The firm's February 28, 2011, response was deemed inadequate. Key violations included a lack of adequate written procedures for production and process controls (21 C.F.R. § 211.100(a)), specifically concerning inadequate process validation for Fentanyl Transdermal System and the Fentanyl Adhesive Mass Solution mixing process. The firm also failed to ensure equipment performed satisfactorily (21 C.F.R. § 211.68(a)), citing inadequate qualification of a cutting/packing machine and a checkweigher. Furthermore, Noven Pharmaceuticals did not thoroughly investigate unexplained discrepancies or batch failures (21 C.F.R. § 211.192), such as defects in Fentanyl Transdermal System pouches and customer complaints of missing patches. Deficiencies in exercising appropriate controls over computer systems (21 C.F.R § 211.68(b)), particularly regarding server backups, and a failure to determine actual and theoretical yields at appropriate manufacturing phases (21 C.F.R § 211.103) were also cited. The FDA requires prompt corrective actions within fifteen working days, with potential legal action, impact on federal contracts, and withholding of drug approvals if violations are not addressed.

Company
Noven Pharmaceuticals, Inc.
Inspection date
February 14, 2011
Product type
Drugs
Office
Department of Health and Human Services
People
  • Alonza E. Cruse (Director)
  • Ingeborg Small
View Company Profile

ID · b319ddec-a6b7-44df-95f2-cb9980583d51

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.100(a)21 CFR 211.68(a)21 CFR 211.19221 CFR 211.68(b)21 CFR 211.103FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Noven Pharmaceuticals, Inc.
  • WARNING_LETTER - 2007-07-02July 2, 2007

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Noven Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.